The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
500
Oral milsaperidone
Oral placebo
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a clinician-rated 10 item scale. Individual item scores are summed for a total possible score of 0 to 60 with a higher score indicating increased severity of depressive symptoms.
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vanda Investigational Site
Phoenix, Arizona, United States
RECRUITINGVanda Investigational Site
Little Rock, Arkansas, United States
RECRUITINGVanda Investigational Site
Garden Grove, California, United States
RECRUITINGVanda Investigational Site
Orange, California, United States
RECRUITINGVanda Investigational Site
Redlands, California, United States
RECRUITINGVanda Investigational Site
San Jose, California, United States
RECRUITINGVanda Investigational Site
Walnut Creek, California, United States
RECRUITINGVanda Investigational Site
Colorado Springs, Colorado, United States
RECRUITINGVanda Investigational Site
Fort Myers, Florida, United States
RECRUITINGVanda Investigational Site
Miami, Florida, United States
ACTIVE_NOT_RECRUITING...and 43 more locations